Back

Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

3 September 2019 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Glucose abnormalities and left ventricular dysfunction Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Elisabetta Patorno

Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
The impact of diabetes mellitus on global longitudinal strain of patients with acute heart failure
Doctor S. Kwak (Seoul, KR)
Abstract Slides
Presentation thumbnail
Peripheral neuropathy and increased risk of heart failure: a population-based longitudinal cohort study
Professor C. Lang (Dundee, GB)
Abstract Slides
Presentation thumbnail
Diagnostic and prognostic utilities of insulin-like growth factor-binding protein-7 in patients presenting to the emergency department with dyspnea: results from the ICON-RELOADED study
Doctor N. Ibrahim (Boston, US)
Abstract Slides
Presentation thumbnail
Metformin reduces the risk of hospitalization for heart failure in type 2 diabetes patients: a retrospective cohort analysis
Doctor C. Tseng (New Taipei, TW)
Abstract Slides
Presentation thumbnail
Acute natriuretic activity of sodium-glucose cotransporter 2 inhibitor in heart failure patients with type 2 diabetes mellitus
Doctor S. Fukuoka (Tsu, JP)
Abstract Slides

Access the full session

Session thumbnail
Glucose abnormalities and left ventricular dysfunction

The Event

Event poster

ESC Congress 2019

3 September 2019 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources